CYCN (Cyclerion Therapeutics) Payments of Debt: $0.00 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CYCN Cyclerion Therapeutics Inc CYCN
33 GF Score
Price $23.94
! 3 Warning Signs
View Full Analysis

What is Cyclerion Therapeutics Payments of Debt?

Cyclerion Therapeutics CYCN -20.19% 33 Payments of Debt is $0.00 Mil as of Jun. 2026. GuruFocus rates CYCN with a GF Score™ of 33/100. The stock has 3 warning signs investors should review.

Cyclerion Therapeutics's Payments of Debt for the three months ended in Jun. 2026 was $0.00 Mil.

Cyclerion Therapeutics's Payments of Debt for the trailing twelve months (TTM) ended in Jun. 2026 was $0.00 Mil.

Cyclerion Therapeutics Payments of Debt Related Terms

Cyclerion Therapeutics Payments of Debt Historical Data

* Premium members only.

The historical data trend for Cyclerion Therapeutics's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cyclerion Therapeutics Payments of Debt Chart

Cyclerion Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Payments of Debt
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

Cyclerion Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Payments of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CYCN
33GF Score
Cyclerion Therapeutics Inc CYCN
Payments of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cyclerion Therapeutics Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

Payments of Debt for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Payments of Debt →
What does a Payments of Debt of $0.00 Mil mean?
Cyclerion Therapeutics (CYCN) has a Payments of Debt of $0.00 Mil as of Jun. 2026. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Cyclerion Therapeutics and its competitors.
Is Cyclerion Therapeutics' Payments of Debt too high?
Cyclerion Therapeutics' current Payments of Debt is $0.00 Mil. Overall, Cyclerion Therapeutics has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Cyclerion Therapeutics' Payments of Debt compare to LPCN and TPST?
Cyclerion Therapeutics' Payments of Debt of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Payments of Debt for a Biotechnology company?
A good Payments of Debt depends on the Biotechnology industry context. However, Payments of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Payments of Debt mean?
A high Payments of Debt can signal that a stock is expensive relative to its fundamentals. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Cyclerion Therapeutics and its competitors. Cyclerion Therapeutics's current Payments of Debt is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cyclerion Therapeutics stock overvalued right now?
Cyclerion Therapeutics (CYCN) has a current Payments of Debt of $0.00 Mil. The current Payments of Debt is $0.00 Mil. Cyclerion Therapeutics' overall GF Score™ is 33/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Payments of Debt calculated?
Payments of Debt is calculated from a company's financial statements. For Cyclerion Therapeutics (CYCN), the current Payments of Debt is $0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cyclerion Therapeutics Business Description

Address 245 First Street, 18th Floor, Cambridge, MA, USA, 02142
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. The company focuses on enabling the full therapeutic potential of next-generation sGC stimulators and neuropsychiatric diseases. Its pipeline products include Olinciguat, Praliciguat, and others.
33GF Score

Get the complete analysis for CYCN

Payments of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$23.94
Price